VERTEX PHARMACEUTICALS INC / MA Inventory, Finished Goods, Net of Reserves
VERTEX PHARMACEUTICALS INC / MA (VRTX) had Inventory, Finished Goods, Net of Reserves of $278.20 million as of 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Notes › Inventory, Net, Items Net of Reserve Alternative › Inventory, Finished Goods and Work in Process, Net of Reserves
us-gaap:InventoryFinishedGoodsNetOfReserves · last filed 2026-08-04
- 2026-06-30: Inventory, Finished Goods, Net of Reserves $278.20M.
- 2026-03-31: Inventory, Finished Goods, Net of Reserves $255.90M.
- 2025-12-31: Inventory, Finished Goods, Net of Reserves $230.10M.
- 2025-09-30: Inventory, Finished Goods, Net of Reserves $252.00M.
| Period end | Inventory, Finished Goods, Net of Reserves | Inventory, Finished Goods, Net of Reserves as first filed |
|---|---|---|
| 2026-06-30 | $278.20M 10-Q · filed 2026-08-04 | |
| 2026-03-31 | $255.90M 10-Q · filed 2026-05-05 | |
| 2025-12-31 | $230.10M 10-Q · filed 2026-08-04 | |
| 2025-09-30 | $252.00M 10-Q · filed 2025-11-04 | |
| 2025-06-30 | $214.30M 10-Q · filed 2025-08-05 | |
| 2025-03-31 | $208.00M 10-Q · filed 2025-05-06 | |
| 2024-12-31 | $184.60M 10-K · filed 2026-02-13 | |
| 2024-09-30 | $188.60M 10-Q · filed 2024-11-05 | |
| 2024-06-30 | $144.90M 10-Q · filed 2024-08-02 | |
| 2024-03-31 | $115.60M 10-Q · filed 2024-05-07 | |
| 2023-12-31 | $135.00M 10-K · filed 2025-02-13 | |
| 2023-09-30 | $112.90M 10-Q · filed 2023-11-07 | |
| 2023-06-30 | $132.80M 10-Q · filed 2023-08-02 | |
| 2023-03-31 | $135.90M 10-Q · filed 2023-05-02 | |
| 2022-12-31 | $161.80M 10-K · filed 2024-02-15 | |
| 2022-09-30 | $126.70M 10-Q · filed 2022-10-28 | |
| 2022-06-30 | $100.70M 10-Q · filed 2022-08-05 | |
| 2022-03-31 | $90.90M 10-Q · filed 2022-05-06 | |
| 2021-12-31 | $86.70M 10-K · filed 2023-02-10 | |
| 2021-09-30 | $94.82M 10-Q · filed 2021-11-03 | |
| 2021-06-30 | $91.22M 10-Q · filed 2021-07-30 | |
| 2021-03-31 | $83.22M 10-Q · filed 2021-04-30 | |
| 2020-12-31 | $73.30M 10-K · filed 2022-02-09 | $73.22M 10-K · filed 2021-02-11 |
| 2020-09-30 | $67.70M 10-Q · filed 2020-10-30 | |
| 2020-06-30 | $54.17M 10-Q · filed 2020-07-31 | |
| 2020-03-31 | $44.83M 10-Q · filed 2020-05-01 | |
| 2019-12-31 | $34.23M 10-K · filed 2021-02-11 | |
| 2019-09-30 | $35.35M 10-Q · filed 2019-10-31 | |
| 2019-06-30 | $38.19M 10-Q · filed 2019-08-01 | |
| 2019-03-31 | $44.52M 10-Q · filed 2019-05-01 | |
| 2018-12-31 | $26.74M 10-K · filed 2020-02-13 | |
| 2018-09-30 | $33.02M 10-Q · filed 2018-10-25 | |
| 2018-06-30 | $24.08M 10-Q · filed 2018-07-26 | |
| 2018-03-31 | $21.53M 10-Q · filed 2018-04-27 | |
| 2017-12-31 | $16.67M 10-K · filed 2019-02-13 | |
| 2017-09-30 | $17.69M 10-Q · filed 2017-10-30 | |
| 2017-06-30 | $15.27M 10-Q · filed 2017-07-28 | |
| 2017-03-31 | $11.93M 10-Q · filed 2017-04-28 | |
| 2016-12-31 | $14.58M 10-K · filed 2018-02-15 | |
| 2016-09-30 | $15.92M 10-Q · filed 2016-10-31 | |
| 2016-06-30 | $15.37M 10-Q · filed 2016-08-01 | |
| 2016-03-31 | $15.37M 10-Q · filed 2016-05-03 | |
| 2015-12-31 | $7.82M 10-K · filed 2017-02-23 | |
| 2015-09-30 | $6.41M 10-Q · filed 2015-10-30 | |
| 2015-06-30 | $2.98M 10-Q · filed 2015-08-04 | |
| 2015-03-31 | $3.69M 10-Q · filed 2015-05-04 | |
| 2014-12-31 | $1.83M 10-K · filed 2016-02-16 | |
| 2014-09-30 | $2.45M 10-Q · filed 2014-11-06 | |
| 2014-06-30 | $969.00K 10-Q · filed 2014-07-31 | |
| 2014-03-31 | $1.82M 10-Q · filed 2014-05-05 | |
| 2013-12-31 | $3.68M 10-K · filed 2015-02-13 | |
| 2013-09-30 | $5.33M 10-Q · filed 2013-11-07 | |
| 2013-06-30 | $11.75M 10-Q · filed 2013-08-02 | |
| 2013-03-31 | $13.81M 10-Q · filed 2013-05-08 | |
| 2012-12-31 | $15.39M 10-K · filed 2014-02-11 | |
| 2012-09-30 | $23.32M 10-Q · filed 2012-11-06 | |
| 2012-06-30 | $23.51M 10-Q · filed 2012-08-08 | |
| 2012-03-31 | $26.34M 10-Q · filed 2012-05-10 | |
| 2011-12-31 | $33.21M 10-K · filed 2013-03-01 | |
| 2011-09-30 | $12.01M 10-Q · filed 2011-11-03 | |
| 2011-06-30 | $1.58M 10-Q · filed 2011-08-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |